Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II

NCT02230176 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

84

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Neuroendocrine Carcinoma

Interventions

DRUG: Sunitinib
DRUG: 177Lu-DOTA0-Tyr3-Octreotate

Sponsor

Gustave Roussy, Cancer Campus, Grand Paris

Collaborators

[object Object]
[object Object]